Trial Number



Respiratory Syncytial Virus (RSV)

Participant Age Range

pre-term and full-term infants

Participant Gender


Enrolling Participants



A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants

The MK-1654-004 study is being conducted to assess the efficacy and safety, along with PK, of MK-1654 for the prevention of RSV-associated MALRI in healthy pre-term and full-term infants. The study will enroll participants with a chronological age up to 1 year and entering the first RSV season at the time of consent; infants 0 through 8 months (i.e., up to 8 months and 29 days) of age at the time of consent will comprise at least 90% of the participants.

Related Clinical Trials

Click on the category you are interested in.

Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.